NXEN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NXEN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nexien BioPharma's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Nexien BioPharma couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.
The historical rank and industry rank for Nexien BioPharma's Cash-to-Debt or its related term are showing as below:
During the past 8 years, Nexien BioPharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 1.39.
The historical data trend for Nexien BioPharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Nexien BioPharma Annual Data | |||||||||||||||||
Trend | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||
Cash-to-Debt | Get a 7-Day Free Trial | 0.92 | 1.39 | 0.53 | 0.13 | 0.01 |
Nexien BioPharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cash-to-Debt | Get a 7-Day Free Trial | 0.08 | 0.01 | 0.03 | 0.01 | 0.02 |
For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Nexien BioPharma's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Nexien BioPharma's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 0.004 | / | (0.312 | + | 0) | |
= | 0.01 |
Nexien BioPharma's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 0.005 | / | (0.328 | + | 0) | |
= | 0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexien BioPharma (OTCPK:NXEN) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Nexien BioPharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey Friedland | other: Former 10% Owner | 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246 |
Kanativa Usa Inc. | 10 percent owner | 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246 |
Kanativa Inc. | 10 percent owner | 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246 |
Joseph F Aceto | officer: VP Legal & IP Counsel | 1617 NEWARK ROAD, KENNETT SQUARE PA 19348 |
Jeremy Robert Reeh | officer: VP Translational Research | 11 TANKARD LANE, WASHINGTON CROSSING PA 18977 |
Alexander Michael Wasyl | director, officer: Chief Executive Officer | 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977 |
Frank J Manganella | officer: VP Corporate Development | 148-26 10TH AVENUE, WHITESTONE NY 11357 |
Clark Courtney Lynne | director | PO BOX 7801, ASPEN CO 81612 |
Lindy Snider | director | 408 BARBARA LANE, BRYN MAWR PA 19010 |
Robert I Goldfarb | officer: Chief Operating Officer | 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160 |
Evan L Wasoff | officer: Chief Financial Officer | 101 WINGER DRIVE, NEDERLAND CO 80466 |
Alain D Bankier | director | 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023 |
Richard S Greenberg | director, 10 percent owner | 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246 |
Ivo Heiden | director, 10 percent owner | 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108 |
From GuruFocus
By ACCESSWIRE AccessWire • 04-12-2019
By Marketwired Marketwired • 12-06-2018
By ACCESSWIRE AccessWire • 04-12-2019
By Marketwired Marketwired • 11-28-2018
By ACCESSWIRE AccessWire • 04-12-2019
By Marketwired Marketwired • 02-19-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.